Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Head and Neck Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02105636
What this trial is testing

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Bristol-Myers Squibb 361
Testing effectiveness (Phase 2)UnknownNCT00003327
What this trial is testing

Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

Who this might be right for
Head and Neck Cancer
Theradex 60
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Testing effectiveness (Phase 2)Looking for participantsNCT06007924
What this trial is testing

Avutometinib and Defactinib in People With Thyroid Cancer

Who this might be right for
Thyroid Cancer
Memorial Sloan Kettering Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Early research (Phase 1)Ended earlyNCT04762225
What this trial is testing

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Who this might be right for
Head and Neck Squamous Cell CarcinomaMelanomaCervical Cancer
Repertoire Immune Medicines 7
Not applicableStudy completedNCT06367010
What this trial is testing

Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

Who this might be right for
Thyroid Neoplasms
Jiangxi Provincial Cancer Hospital 8
Early research (Phase 1)Study completedNCT01520389
What this trial is testing

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Who this might be right for
Advanced Solid TumorsColorectal CancerSquamous Cell Head and Neck Cancer+2 more
Merrimack Pharmaceuticals 112
Not applicableStudy completedNCT00848042
What this trial is testing

Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck

Who this might be right for
Head and Neck Cancer
Nanospectra Biosciences, Inc. 11
Testing effectiveness (Phase 2)Study completedNCT00004070
What this trial is testing

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Who this might be right for
Head and Neck Cancer
Dana-Farber Cancer Institute 7
Very early researchUnknownNCT05830240
What this trial is testing

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

Who this might be right for
Head and Neck CancerEsophageal CancerOtorhinolaryngologic Neoplasms+4 more
Shanghai Yunying Medical Technology 9
Testing effectiveness (Phase 2)Ended earlyNCT01333852
What this trial is testing

Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer

Who this might be right for
Head and Neck NeoplasmsSquamous Cell Carcinoma
Lucas Vieira dos Santos 45
Testing effectiveness (Phase 2)UnknownNCT01377298
What this trial is testing

Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
National Taiwan University Hospital 45
Testing effectiveness (Phase 2)Study completedNCT00784303
What this trial is testing

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Who this might be right for
Thyroid Cancer
Eisai Inc. 117
Testing effectiveness (Phase 2)WithdrawnNCT04832438
What this trial is testing

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Who this might be right for
Salivary Gland CarcinomaAdenoid Cystic CarcinomaSalivary Gland Cancer+1 more
Actuate Therapeutics Inc.
Testing effectiveness (Phase 2)Study completedNCT00397904
What this trial is testing

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT00702884
What this trial is testing

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal Cancer
Tony Bekaii-Saab 25
Not applicableStudy completedNCT06362772
What this trial is testing

Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Jiangxi Provincial Cancer Hospital 36
Early research (Phase 1)Temporarily pausedNCT05400122
What this trial is testing

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Who this might be right for
Colorectal CancerHematologic MalignancyRectum Cancer+15 more
David Wald 12
Not applicableApproved For MarketingNCT02211222
What this trial is testing

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Eisai Inc.
Next Page